1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow dr. Tom van der Hulle: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabozantinib Dose Skipping as an Alternative to Dose Reductions Cabozantinib - Renal Cell Carcinoma (RCC) | Phase 2 | Recruiting | dr. Tom van der Hulle | 34 | 2026-01-26 | 2026-08-31 |
| The Pharmacological Effects of Using Cabozantinib With a Light Breakfast Light breakfast - Renal Cell Carcinoma | Phase 2 | Completed | dr. Tom van der Hulle | 12 | 2023-05-25 | 2025-09-03 |
Carcinoma, Renal Cell (2) · Carcinoma (1)
cabozantinib (1)
Netherlands (2)
2025 (1)